These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30166469)

  • 1. In dogs, CRISPR fixes a muscular dystrophy.
    Cohen J
    Science; 2018 Aug; 361(6405):835. PubMed ID: 30166469
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.
    Nelson CE; Hakim CH; Ousterout DG; Thakore PI; Moreb EA; Castellanos Rivera RM; Madhavan S; Pan X; Ran FA; Yan WX; Asokan A; Zhang F; Duan D; Gersbach CA
    Science; 2016 Jan; 351(6271):403-7. PubMed ID: 26721684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
    Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R
    Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR Correction of Duchenne Muscular Dystrophy.
    Min YL; Bassel-Duby R; Olson EN
    Annu Rev Med; 2019 Jan; 70():239-255. PubMed ID: 30379597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Editing for Duchenne Muscular Dystrophy Using the CRISPR/Cas9 Technology: The Importance of Fine-tuning the Approach.
    Tremblay JP; Iyombe-Engembe JP; Duchêne B; Ouellet DL
    Mol Ther; 2016 Nov; 24(11):1888-1889. PubMed ID: 27916992
    [No Abstract]   [Full Text] [Related]  

  • 6. Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients.
    Duan D
    Hum Gene Ther; 2018 Jul; 29(7):733-736. PubMed ID: 29463117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress toward Gene Therapy for Duchenne Muscular Dystrophy.
    Chamberlain JR; Chamberlain JS
    Mol Ther; 2017 May; 25(5):1125-1131. PubMed ID: 28416280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy.
    Mata López S; Balog-Alvarez C; Vitha S; Bettis AK; Canessa EH; Kornegay JN; Nghiem PP
    PLoS One; 2020; 15(1):e0228072. PubMed ID: 31961902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
    Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
    Choi E; Koo T
    Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene-Editing Technology Accelerates Cardiovascular Research: Clinical Applications Being Explored.
    Kuehn BM
    Circulation; 2018 Feb; 137(9):973-974. PubMed ID: 29483173
    [No Abstract]   [Full Text] [Related]  

  • 12. CRISPR therapy shows promise in Duchenne muscular dystrophy.
    Ridler C
    Nat Rev Neurol; 2018 Nov; 14(11):632-633. PubMed ID: 30237553
    [No Abstract]   [Full Text] [Related]  

  • 13. AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice.
    Hakim CH; Wasala NB; Nelson CE; Wasala LP; Yue Y; Louderman JA; Lessa TB; Dai A; Zhang K; Jenkins GJ; Nance ME; Pan X; Kodippili K; Yang NN; Chen SJ; Gersbach CA; Duan D
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cautious welcome for gene editing of Duchenne muscular dystrophy in animal model.
    Hawkes N
    BMJ; 2016 Jan; 351():h7033. PubMed ID: 26729900
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical and genetic characterisation of dystrophin-deficient muscular dystrophy in a family of Miniature Poodle dogs.
    Sánchez L; Beltrán E; de Stefani A; Guo LT; Shea A; Shelton GD; De Risio L; Burmeister LM
    PLoS One; 2018; 13(2):e0193372. PubMed ID: 29474464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
    Cerletti M; Negri T; Cozzi F; Colpo R; Andreetta F; Croci D; Davies KE; Cornelio F; Pozza O; Karpati G; Gilbert R; Mora M
    Gene Ther; 2003 May; 10(9):750-7. PubMed ID: 12704413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy.
    Rodino-Klapac LR; Janssen PM; Montgomery CL; Coley BD; Chicoine LG; Clark KR; Mendell JR
    J Transl Med; 2007 Sep; 5():45. PubMed ID: 17892583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
    Long C; Amoasii L; Bassel-Duby R; Olson EN
    JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength.
    Martin PT; Zygmunt DA; Ashbrook A; Hamilton S; Packer D; Birch SM; Bettis AK; Balog-Alvarez CJ; Guo LJ; Nghiem PP; Kornegay JN
    PLoS One; 2021; 16(3):e0248721. PubMed ID: 33770101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives.
    Chen G; Wei T; Yang H; Li G; Li H
    Cells; 2022 Sep; 11(19):. PubMed ID: 36230926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.